Stock Alert: Aprea Tanks 80% After Blood Cancer Drug Trial Fails To Meet Main Goal

Shares of Aprea Therapeutics Inc. (APRE) are currently plunging nearly 80% after the biopharmaceutical company focused on cancer therapy said a late-stage trial of blood cancer drug failed to meet primary endpoint.

APRE is currently trading at $5.69, down $19.40 or 77.32% on Nasdaq.

Aprea Therapeutics announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine versus AZA alone in TP53 mutant myelodysplastic syndromes. The trial did not meet the primary endpoint of complete remission rate.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, said it is launching more options on WhatsApp to control their messages and how long they stick around, with default disappearing messages and multiple durations. The latest features are expected to bring more control and privacy on the popular messaging app. Delivery services company DoorDash has introduced ultra-fast grocery deliveries with DashMart in Chelsea, New York City. The company said it aims to deliver in 10-15 minutes and plans to expand its new service in select DoorDash grocery and convenience partners over the next year. With over 2,000 items, DashMart offers a wide assortment of fresh and frozen grocery staples, snacks, household goods, and local products. Ontario, Canada-based Erie Meat Products Ltd. is recalling approximately 1,224 pounds of fully cooked chicken bologna products, according to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS. The chicken bologna products were imported and distributed into the United States without the benefit of FSIS import reinspection.
Follow RTT